1094772-18-5

Basic information

• Product Name: 3-(2-nitrosophenyl)propionic acid
• Synonyms: 3-(2-nitrosophenyl)propionic acid
• CAS NO: 1094772-18-5
• Molecular Weight: 179.175
• Mol File: 1094772-18-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-(2-nitrosophenyl)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-nitrosophenyl)propionic acid(1094772-18-5)
• EPA Substance Registry System: 3-(2-nitrosophenyl)propionic acid(1094772-18-5)

Safety Data

• Hazardous Substances Data: 1094772-18-5(Hazardous Substances Data)

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 771-19-7 1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline 
• 612-41-9 2-nitrocinnamic acid 
• 2666-20-8 sodium 3-(2-aminophenyl)propionate 
• 772-21-4 3-(2-aminophenyl)propanoic acid 

Downstream Products

• 1094772-33-4 [2-(2,2-dimethyl-4-oxo-4H-benzo[1,3]dioxin-6-ylazo)-phenyl]-propionic acid 
• 1094772-24-3 5-[2-(2-carboxyethyl)phenylazo]-2-hydroxybenzoic acid tert-butyl ester 
• 1233497-42-1 C₂₀H₂₂N₂O₄ 
• 1415405-06-9 C₁₈H₁₇N₃O₅ 
• 1415405-03-6 C₂₀H₂₂N₂O₄ 
• 1094772-46-9 C₃₇H₄₀N₂O₈ 
• 1415405-04-7 C₄₁H₄₈N₂O₈ 
• 1415405-05-8 C₁₆H₁₄N₂O₄ 

Relevant articles and documents

A class of intestinal lysis type co-drugs and their preparation and use

The present invention relates to a class of intestinal cleavage type co-drugs (Codrug) and preparation and use thereof, in particular, the present invention provides a co-drug compound as shown in formula I. The present invention further provides a method

TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Provided herein are compounds, compositions and methods for preventing or treating gastrointestinal cancer in a mammal, wherein the method comprises delivering an effective amount of a COX-2 or a similar sulfonamide inhibitor as a prodrug or derivative thereof to the colon, wherein the COX-2 or similar inhibitor is released in- vivo.

TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).